# Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets

> **NCT04171453** · — · UNKNOWN · sponsor: **Viatris Korea** · enrollment: 600 (estimated)

## Conditions studied

- Peripheral Neuropathic Pain

## Interventions

- **DRUG:** Lyrica CR (Pregabalin)

## Key facts

- **NCT ID:** NCT04171453
- **Lead sponsor:** Viatris Korea
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-03
- **Primary completion:** 2022-07-14
- **Final completion:** 2022-07-14
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04171453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04171453, "Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04171453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*